Search Results

CREATE Health: Translational Cancer Center CREATE Health develops and translates cutting-edge diagnostic and therapeutic innovations into real-world clinical solutions that measurably improve patient outcomes and advance public health. We…

https://www.createhealth.lth.se/start- 2025-12-04

Centre Management Sara EkCenter Director, Director CanFastersara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Kristina LundbergDeputy Directorkristina [dot] lundberg [at] immun [dot] lth [dot] se (kristina…

https://www.createhealth.lth.se/about/organization- 2025-12-02

Principle Investigators within CREATE Health have founded several spin-off companies which are already helping patients all around the world. Beside that, tens of research articles with ground-breaking discoveries have been published in…

https://www.createhealth.lth.se/impact- 2025-12-02

 Var god vänta...

https://www.createhealth.lth.se/impact/publications- 2025-12-02

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment- 2025-06-03

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s…

https://www.createhealth.lth.se/about/partners- 2025-12-01

Lead BiologicsLead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique…

https://www.createhealth.lth.se/impact/spin-companies- 2025-12-02

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility…

https://www.createhealth.lth.se/canfaster- 2025-06-04

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh…

https://www.createhealth.lth.se/impact/canfaster-publications- 2025-12-02

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s- 2025-06-10

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy- 2025-06-10

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health…

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer- 2025-06-10

 Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden

https://www.createhealth.lth.se/contact- 2025-12-02

CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic center for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our…

https://www.createhealth.lth.se/about- 2025-12-04

Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific…

https://www.createhealth.lth.se/research- 2025-12-01

Molecular characterisation of breast cancer: biomarkers of risk, prognosis and treatment, Åke Borg, Medical Faculty."The long-term objective is to deepen our understanding of breast cancer etiology through advances in cell biology and…

https://www.createhealth.lth.se/research/research-projects- 2025-12-01

 Please wait...

https://www.createhealth.lth.se/contact/principal-investigators- 2025-12-01

Lead Biologics takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced…

https://www.createhealth.lth.se/article/promising-results-lead-biologics-first-class-checkpoint-inhibitor-published-nature-cancer- 2025-11-27

In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are…

https://www.createhealth.lth.se/about/funding- 2025-06-03

The Mrs Berta Kamprad Foundation is donating SEK 420 million to cancer research at Lund University. This is the largest donation to the university since its foundation in 1666. The donation is dedicated to translational cancer research,…

https://www.createhealth.lth.se/article/sek-420-million-cancer-research-lund-university- 2025-11-27